May 02, 2024
Positive Initial Clinical Data Reported from Immutep’s Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma
Apr 28, 2024
Immutep Quarterly Activities Report Q3 FY24
Apr 23, 2024
Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B
Apr 18, 2024
Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761
Apr 17, 2024
Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer
